Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | DRD4 | P21917 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227751 | 0.87 | CYP2A6 (0.43) | MAPK1CYP1A2CYP2D6TDP1KDM4E | |
| SCHEMBL19537683 | 0.74 | MAPK1 (0.57) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL5228795 | 0.74 | MAPK1 (0.48) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL3883812 | 0.72 | MAPK1 (0.47) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL4499503 | 0.70 | MAPK1 (0.48) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL4846385 | 0.67 | MAPK1 (0.50) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL5228555 | 0.67 | MAPK1 (0.37) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL19537649 | 0.67 | MAPK1 (0.53) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL5227927 | 0.67 | MAPK1 (0.47) | MAPK1ALDH1A1MAPTDRD2DRD4 | |
| SCHEMBL11266316 | 0.66 | MAPK1 (0.53) | MAPK1ALDH1A1MAPTDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312203-B2 | 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GlaxoSmithKline istraziva{hacek over (c)}ki Centar Zagreb d.o.o. (HR) | 2007-12-25 | — | — | US | claimed |
| EP-1506202-B1 | 1-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2007-08-08 | — | — | EP | claimed |
| US-20050209191-A1 | 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-09-22 | — | — | US | claimed |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | claimed |
| EP-1506202-B1 | 1-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2007-08-08 | — | — | EP | disclosed |
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | disclosed |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111968-A1 | 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | MAPK1 2673/4885ALDH1A1 130/4885MAPT 406/4885 |
| US-20050209191-A1 | 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | MAPK1 207/4885ALDH1A1 42/4885MAPT 3373/4885 |
| US-20050148578-A1 | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | MAPK1 223/4885ALDH1A1 44/4885MAPT 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.